In short
Clinical trials investigating SODIUM FUSIDATE are studying treatment for pyogenic vertebral osteomyelitis, a spinal bone infection. The main goal is to see whether an early switch to oral antibiotics is as effective as longer intravenous treatment. These trials focus on adults with this infection and measure death, surgery, relapse, and the need for more IV antibiotics.
Key points
- SODIUM FUSIDATE is being studied in a Phase 3 trial for pyogenic vertebral osteomyelitis, which is a bacterial infection of the spine bones. The study asks whether patients can move to oral antibiotic treatment earlier after one week of IV treatment. It compares this strategy with the current guideline approach of longer IV treatment followed by oral treatment. The trial includes adults with this infection and has an enrollment of 530. Main results include death, unplanned spine surgery, relapse of infection, and the need for more IV antibiotics.
Trial overview
The available trial for SODIUM FUSIDATE is titled “SAVE- oral antibiotics for treatment of vertebral osteomyelitis” and is listed as authorised. It is an interventional study, which means researchers assign a treatment plan and then compare outcomes.
This trial studies people with pyogenic vertebral osteomyelitis, a bacterial infection of the spine bones. The study includes 530 participants and is in Phase 3.
Study design and treatment plan
The main question is whether an early switch to oral antibiotic treatment after one week of intravenous (IV) treatment is non-inferior to the current national guideline approach. Non-inferior means the new plan is not worse than the standard treatment by an important amount.
The current guideline approach described in the trial is continued IV antibiotic treatment for 2 to 4 weeks, followed by oral treatment. The trial compares this with an earlier move to oral antibiotics, and SODIUM FUSIDATE is one of the oral antibiotic options listed in the intervention set.
The intervention list also includes several other antibiotics, which shows that the study is testing a treatment strategy rather than only one single medicine.
Who may participate
The trial is focused on patients with pyogenic vertebral osteomyelitis. The source data do not provide more detailed inclusion or exclusion rules, such as age limits or lab test requirements.
Because the condition is an infection of the spine, the study is aimed at patients who need antibiotic treatment for this serious bone infection.
What the trial measures
The primary outcome is a composite result, which means several important events are grouped together into one main measure. The study tracks these events from the time of switch to oral antibiotic treatment until 6 months after oral treatment ends.
- All-cause mortality: whether any death occurs during the study period.
- Unplanned surgical intervention in relation to the spine: whether a spine operation is needed unexpectedly.
- Relapse of bacteremia with the primary pathogen: whether the bacteria return in the blood.
- Relapse of bacteria found again in material from infected areas near the spine or iliopsoas muscle, confirmed by culture.
- Renewed course of IV antibiotics for more than 7 days for pyogenic vertebral osteomyelitis: whether patients need another long IV treatment period.
Why this study matters
This trial is important because it tests whether patients can move to oral treatment earlier without losing effectiveness. If the early oral strategy works well, it may reduce the time patients need IV treatment and hospital-based care.
For patients, the key point is that the study is not just about one medicine, but about how to safely treat a serious spinal infection with antibiotics, including SODIUM FUSIDATE as one of the oral options.